A Study of LY4064809 in Healthy Adult Chinese Participants

Phase 1 Completed 10 enrolled Eli Lilly and Company Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company · collab

NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants. The study drug will be administered orally. The study will last approximately 21 days, excluding screening.

Timeline

Start: 2025-10-24
Primary completion: 2025-12-16
Completion: 2025-12-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	STX-478	Small molecule	—	Oral

Indications

No indication recorded.